Home › Research › Disease mechanisms
The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies
El-Bakly W, Wagdy O, Sobhy A, Abo Elenain O, Riad MS, El Sayed M, Tarkhan S, Yassen M et al.. Behavioural brain research, 2019-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer disease (AD) initially presents with cognitive decline that affects the affected individual's daily activities. Cognitive decline reversal represents an important medical need, where Phosphodiesterase-5 inhibitors (PDE-5Is) might play a role. Aim This systematic review was performed to verify the efficacy of PDE-5Is in preventing cognitive impairment and to elucidate the underlying mechanism. Methods Preclinical animal studies assessing the efficacy of PDE-5Is in preventing cognitive impairment and pathological changes by measuring Aβ-42 β42 and p-Tau were included in the analysis. CAMARADES Checklist was used to assess study quality. Further, various signaling pathways in different studies were examined. Results and outcomes Data of behavioral tests were extracted and a meta-analysis was conducted. Fifteen animal trials met the inclusion criteria, and all reported the prevention of cognitive deficits by PDE-5Is in Alzheimer's disease. A significant effect of PDE-5Is in increasing the time spent in the target quadrant was reported in four of seven studies using the water maze. Four studies showed significant improvement in contextual fear memory freezing time, and three studies showed improvement in the 14 unit maze number of errors. Conclusions Cognitive decline in preclinical AD finds tauopathy has a more impact than Aβ-42. This systematic review showed that PDE-5 inhibitors might help prevent cognitive impairment in AD, and while its mechanism of action is non-related to Aβ-42, it might include decrease p-Tau, increase CREB and BDNF or suppressing apoptosis and inflammation. However, the efficacy of PDE-5 inhibitors in preventing cognitive impairment remains unclear due to various limitations, such as the small number of included studies, the high risk of bias, the lack of an integrated study design, and low reporting quality.
What this study adds
Evidence grade: High
This is a pooled review. Fifteen animal studies were reviewed and all reported that PDE-5 inhibitors prevented memory problems in Alzheimer's models, possibly by lowering p-Tau and raising CREB and BDNF rather than through Aβ-42. However, the authors say the efficacy remains unclear because of the small number of studies, high risk of bias and low reporting quality.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
El-Bakly, W., Wagdy, O., Sobhy, A., Abo Elenain, O., Riad, M. S., El Sayed, M., et al. (2019). The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies. Behavioural brain research. https://doi.org/10.1016/j.bbr.2019.112004
Vancouver
El-Bakly W, Wagdy O, Sobhy A, Abo Elenain O, Riad MS, El Sayed M, et al. The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies. Behavioural brain research. 2019. doi:10.1016/j.bbr.2019.112004. PMID: 31163203.
BibTeX
@article{elbakly2019-31163203,
author = {El-Bakly, W. and Wagdy, O. and Sobhy, A. and Abo Elenain, O. and Riad, M. S. and El Sayed, M. and Tarkhan, S. and Yassen, M. and others},
title = {{The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies}},
journal = {Behavioural brain research},
year = {2019},
doi = {10.1016/j.bbr.2019.112004},
pmid = {31163203},
url = {https://doi.org/10.1016/j.bbr.2019.112004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results and outcomes Data of behavioral tests were extracted and a meta-analysis was conducted.
- A significant effect of PDE-5Is in increasing the time spent in the target quadrant was reported in four of seven studies using the water maze.
- Four studies showed significant improvement in contextual fear memory freezing time, and three studies showed improvement in the 14 unit maze number of errors.
- This systematic review showed that PDE-5 inhibitors might help prevent cognitive impairment in AD, and while its mechanism of action is non-related to Aβ-42, it might include decrease p-Tau, increase CREB and BDNF or suppressing apoptosis and inflammation.
Why it matters
Fifteen animal studies were reviewed and all reported that PDE-5 inhibitors prevented memory problems in Alzheimer's models, possibly by lowering p-Tau and raising CREB and BDNF rather than through Aβ-42. However, the authors say the efficacy remains unclear because of the small number of studies, high risk of bias and low reporting quality. These are animal findings, so they point to a drug class worth studying rather than a proven prevention for people.
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 51/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Behavioural brain research) |
| Journal's citation record | 3 / 4 | Behavioural Brain Research: journal h-index 252 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 3 / 7 | Cited 15 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 1 / 6 | Cited 0.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Nesreen Nabil holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Ain Shams University: institution h-index 314 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31163203) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 49 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Disease mechanisms from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.